Optimal thiazide dose sought in Japan
A new panel, named the Study Committee on Antihypertensive Diuretics, within Japan's Ministry of Health, Welfare and Labor has been set the task of finding an optimal dose for thiazide diuretics, given this is higher in Japan than in the USA and Europe.
The Japanese Society of Hypertension has called on the MHLW to review the dosages of thiazide diuretics because they are inclined to cause adverse reactions to drugs. For instance, the doses of hydrochlorothiazide in Japan range from 25mg to 100mg while those in the USA are from 12.5mg to 50mg. Dosage levels in Japan were approved more than 40 years ago.
The diuretic brands to be reviewed include: Dichlotride (hydrochlorothiazide) from Merck & Co subsidiary Banyu; Tenaxil from Alfressa Pharma and Natrix from Kyoto Pharmaceutical (both indapamide); Hygroton (chlortalidon) from Novartis; and Fluitoran (trichlormethiazide) from Shionogi.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze